-transparent.png){kind=logo}
Plasma salicylate concentration was monitored in 42 children on long-term salicylate therapy for rheumatoid arthritis. A given dose of salicylate per kg resulted in large variations in plasma levels, both between individuals and for a single individual at different times. The factors responsible for such variations were studied; in 6 cases urinary metabolites of salicylate were analysed. The relation between salicylate dosage and plasma half-life accounts for the fact that small changes in dosage can result in large changes in plasma concentration. The addition of corticosteroid or ACTH therapy results in lower plasma levels of salicylate, and necessitates higher dosage of salicylate. After the introduction of routine monitoring of plasma salicylate, the incidence of toxic symptoms fell sharply.
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
August 1979,
Arthritis and rheumatism,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
August 1970,
The Medical journal of Australia,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
October 1970,
The Medical journal of Australia,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
July 1970,
The Medical journal of Australia,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
January 1977,
Clinical pharmacokinetics,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
January 1973,
Arthritis and rheumatism,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
January 1980,
The Journal of rheumatology,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
June 1987,
Therapeutic drug monitoring,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
January 1978,
Yonsei medical journal,
M Bardare, and
G U Cislaghi, and
M Mandelli, and
F Sereni
February 1984,
British journal of rheumatology,
